The development of new therapies for amyotrophic lateral sclerosis (ALS) does not rely solely on advances in biomedical research at the laboratory level. It also requires the ability to translate that knowledge into the clinical setting in an efficient, safe, and coordinated way. In this context, clinical trials in Spain have become a fundamental pillar within the European ecosystem of pharmaceutical and biotechnology innovation.
Today, Spain stands as one of the most competitive countries for the clinical development of new treatments, particularly in highly complex areas such as neurodegenerative diseases.
A strong ecosystem for pharmaceutical research
In recent years, Spain has strengthened its position as a European benchmark in pharmaceutical research. According to data from the Spanish Agency of Medicines and Medical Devices (AEMPS), nearly 1,000 clinical trials were authorized in 2025, consolidating the country as one of the most active in the European Union.
This leadership is reflected not only in volume, but also in the quality and diversity of studies, with a strong presence in key areas such as rare diseases, advanced therapies, and innovative medicines.
In addition, Spain stands out as a strategic partner in multinational clinical trials, facilitating access to international patient cohorts and accelerating the generation of robust results. Its network of hospitals and research centers—comprising nearly 1,000 institutions—further strengthens its operational capacity and attractiveness for global projects.
Critical points in clinical trials: why the process is so complex
The development of a clinical trial is one of the most demanding processes in pharmaceutical research. It involves not only validating the efficacy of a treatment, but also ensuring patient safety and generating solid scientific evidence.
Some of the most critical aspects include:
- Patient selection and recruitment
In diseases such as ALS, identifying patients at specific stages of the disease to minimize variability is particularly challenging. Inclusion criteria must be highly precise to ensure reliable results. - Trial design
Defining objectives, clinical endpoints, and biomarkers accurately is essential. Poor design can compromise years of research. - Patient safety
The top priority is to ensure that the treatment does not produce severe adverse effects. This requires continuous patient monitoring and highly stringent protocols. - Validation of results
Demonstrating clinical efficacy in neurodegenerative diseases is particularly difficult due to their heterogeneous progression and patient variability. - Regulatory compliance
Each phase must meet demanding national and international standards, requiring ongoing coordination with regulatory agencies. - Scalability and future viability
Trials must be designed with later phases and potential commercialization in mind, adding an additional layer of strategic complexity.
In this context, the implications are significant: not only the viability of a therapeutic candidate, but also the possibility of offering new options to patients who currently lack effective treatments.
Talent and expertise in biotechnology
One of the country’s greatest strengths is its human capital. Spain has highly qualified professionals in biotechnology, clinical development, and biomedical research, including neurologists, researchers, and specialized clinical trial units.
Initiatives such as SCReN (Spanish Clinical Research Network) facilitate coordination among centers and promote scientific excellence at the national level. In conditions like ALS, where biological complexity demands multidisciplinary approaches, this collaboration is particularly critical.
Spain in the context of European innovation
Being part of the European ecosystem provides additional advantages for pharmaceutical and biotechnology research. Spain actively participates in funding and innovation programs such as Horizon Europe, which supports collaborative projects in key areas including health, personalized medicine, and neurodegenerative diseases.
Beyond funding, these programs foster the integration of scientific capabilities across Europe, facilitating access to shared infrastructures, biomedical data, and international research networks. This is particularly relevant in diseases such as ALS, where biological complexity and low prevalence require large cohorts, multidisciplinary approaches, and validation across multiple clinical settings.
In this context, European collaboration enables more robust research models, integrating everything from molecular biology to clinical development, and supporting the identification of new therapeutic targets and more precise strategies. This coordinated approach is essential to accelerate the translation of basic research into clinical practice and improve the likelihood of success in developing new therapies.
Why this is key for ALS
In the case of ALS, this capability is especially critical due to the rapid progression of the disease and the narrow therapeutic window for intervention. Clinical trials require identifying and recruiting patients at specific stages, as well as precisely monitoring disease progression using increasingly sophisticated biomarkers and functional tools.
Moreover, the growing integration of patient-based models, molecular biomarkers, and personalized medicine approaches is transforming how ALS trials are designed, enabling better patient stratification and more accurate evaluation of treatment effects. In this context, having environments capable of integrating these approaches is essential to advance toward more effective therapies tailored to the real biology of the disease.
Looking ahead
The future of ALS research will depend on the ability to effectively connect science and clinical practice. In this process, Spain is emerging as a strategic environment to drive pharmaceutical innovation and bring new therapies closer to patients.
At Molefy Pharma, we understand that real progress is only possible when scientific excellence is combined with the right clinical environment. That is why we are committed to models that integrate research, development, and clinical application in collaboration with regulatory bodies, with the goal of generating tangible impact on patients’ lives.